Back to Search
Start Over
Geron Announces Completion of Patient Enrollment in IMerge Phase 3 Clinical Trial in Lower Risk Myelodysplastic Syndromes
- Source :
- Business Wire. October 18, 2021
- Publication Year :
- 2021
-
Abstract
- Top-Line Results Expected at the Beginning of January 2023 FOSTER CITY, Calif. -- Geron Corporation (Nasdaq: GERN), a late-stage biopharmaceutical company focused on the development and commercialization of treatments for [...]
Details
- Language :
- English
- Database :
- Gale General OneFile
- Journal :
- Business Wire
- Publication Type :
- News
- Accession number :
- edsgcl.679303324